<DOC>
	<DOCNO>NCT00950950</DOCNO>
	<brief_summary>The purpose study evaluate effect AMG 785 parameter bone quality forearm use peripheral Quantitative Computed Tomography ( pQCT ) follow multiple subcutaneous dose administration AMG 785 postmenopausal woman low bone mass .</brief_summary>
	<brief_title>A Study Evaluate Effect AMG 785 Bone Quality Forearm Postmenopausal Women With Low Bone Mass</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Healthy female 55 80 year age Postmenopausal female ( base medical history ) define 12 continuous month spontaneous amenorrhea Women 60 year age old consider postmenopausal Women 5559 must serum folliclestimulating hormone result ≥ 40mIU/mL serum estradiol ≤ 20 pg/mL Low bone mineral density [ BMD , Tscore 1.0 2.5 lumbar spine ( L1L4 ) and/or femoral neck ] Weight ≤ 98 kg ( 216 lb ) and/or height ≤ 196 cm ( 77 ) 25hydroxyvitamin D ≥ 20 ng/mL screen Willing able take ≥ 500 mg calcium ≥ 400 IU ( ≤ 1,000 IU ) vitamin D daily Osteoporosis , define BMD Tscore ≤ 2.5 lumbar spine femoral neck History vertebral fracture , fragility fracture wrist , humerus , hip pelvis Diagnosed condition affect bone metabolism Subjects few 2 evaluable vertebra ; metal forearm bilaterally would allow least one evaluable forearm Administration follow medication within 6 month study drug administration . This include rout administration , example intranasal topical skin patch , unless otherwise note : Hormone replacement therapy [ ( eg , estrogen , estrogenlike compound raloxifene ) . Infrequent use estrogen vaginal cream ( &lt; 3 time per week ) allow . ] Calcitonin Parathyroid hormone ( derivative ) Glucocorticosteroids ( inhaled topical corticosteroid administer 2 week enrollment date allow ) Anabolic steroid Calcitriol , available analogue Administration daily , weekly , monthly bisphosphonates ( BP ) unless meet follow criterion : &lt; 2 week BP use require 2month washout period 2 week 3 month BP use require 9month washout period 3 6 month BP use require 1year washout period &gt; 6 month BP use require 3year washout period ; Greatly differ level physical activity constant level intense physical exercise 6 month study drug administration Known sensitivity mammalianderived drug preparation Known hepatitis B surface antigen , hepatitis C virus Human Immunodeficiency Virus positive know diagnosis Acquired Immunodeficiency Syndrome Any organic psychiatric disorder , , opinion investigator , pose risk subject safety may prevent subject complete study interfere interpretation study result Unavailable followup assessment concern subject 's compliance protocol procedures Any condition might reduce chance obtain data require protocol might compromise ability give truly informed consent History evidence clinically significant disorder , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedures completion Clinically significant abnormality screen physical examination , ECG laboratory evaluation Participation another clinical study within 4 week screen within 5 time halflife investigational agent clinical study , know Has donate lose 400 mL blood plasma within 8 week study drug administration Previous AMG 785 exposure</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Bone Density</keyword>
</DOC>